跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 18,649 条关于
“JAK2 V617F selective inhibitors”
全部
18,649
临床试验
9,380
药物
3,385
机构
17
资讯
5,867
9个月前
Atavistik Bio Unveils Novel JAK2 V617F Mutant-Selective Inhibitors for Myeloproliferative Neoplasms at ASH 2025
去年
Vanda Pharmaceuticals' VGT-1849A, a Selective JAK2 Inhibitor, Receives FDA Orphan Drug Designation for Polycythemia Vera
去年
Vanda Pharmaceuticals Receives FDA Orphan Drug Designation for Novel JAK2-Selective Antisense Therapy VGT-1849B in Polycythemia Vera
10个月前
Eilean Therapeutics' First-in-Class MALT1 Degrader TE205 Shows Promising Efficacy in Ulcerative Colitis Preclinical Studies
9个月前
Prelude Therapeutics Unveils Novel JAK2V617F-Selective Inhibitor and mCALR-Targeted Therapy for Myeloproliferative Neoplasms
去年
Phase 1 Trial of Type II JAK2 Inhibitor AJ1-11095 Underway for Myelofibrosis
24天前
Combination of JAK2 and PARP Inhibitors Shows Early Promise in Phase 1 Trial for Myelofibrosis
去年
Saruparib Shows Promise as Selective PARP1 Inhibitor in Advanced Solid Tumors
去年
FDA Grants Fast Track Designation to Sumitomo's Nuvisertib for Myelofibrosis Treatment
4个月前
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion to Advance Novel JAK2 Inhibitor for Blood Cancers
第 1 页,共 587 页
上一页
下一页